Diagnostic challenges and role of immunohistochemistry in metastatic liver disease
Muhammad Tahir Khadim1, Shahid Jamal, Zafar Ali
1Department of Histopathology, Armed Forces Institute of Pathology, Rawalpindi, Pakistan. mtkhadim@hotmail.com
Insights
Immunohistochemistry (IHC) aids in diagnosing metastatic liver disease by analyzing primary tumor sites. However, no single IHC panel is universally effective; selection depends on morphology, history, and other tests.
Area of Science:
- Histopathology
- Oncology
- Diagnostic Pathology
Background:
- Metastatic liver disease diagnosis can be challenging.
- Immunohistochemistry (IHC) is a valuable tool in surgical pathology.
- Accurate primary tumor site identification is crucial for patient management.
Purpose of the Study:
- To evaluate the diagnostic utility of Immunohistochemistry (IHC) for metastatic liver disease.
- To identify the most common primary tumor sites in liver metastases.
Main Methods:
- A descriptive, cross-sectional study of 130 metastatic liver disease cases.
- Review of Hematoxylin and Eosin stained sections.
- Application and evaluation of specific Immunohistochemistry marker panels.
Main Results:
- The study included 87 males (67%) and 43 females (33.07%).
- The most frequent primary sites were Gastrointestinal Tract (GIT) (45%), followed by neuroendocrine carcinoma and gallbladder.
- Less common primary sites included lung, breast, ovary, and thyroid.
Conclusions:
- No single Immunohistochemistry panel is definitive for all metastatic liver tumors.
- Optimal IHC marker selection requires integration of morphological features, clinical history, and ancillary investigations.
Objective:
To evaluate the role of Immunohistochemistry (IHC) in the diagnosis of metastatic liver disease, with a descriptive, cross-sectional study at the Department of Histopathology, Armed Forces Institute of Pathology (AFIP), Rawalpindi.
Material And Methods:
A total of 130 cases of metastatic liver disease were retrieved from the tumor registry data. Eosin-haematoxylin stained sections and Immunohistochemistry panels applied to ascertain the site of primary tumor were evaluated. The panels of detailed immunohistochemical markers were applied. Frequency and percentages were calculated for qualitative variables. Mean and standard deviations were calculated for quantitative variables.
Results:
Males were 87 (67%) and were females 43 (33.07%). The most common site of primary was in GIT (45%), followed by neuroendocrine carcinoma and gall bladder. The other less common sites were lung, breast, ovary and thyroid.
Conclusion:
There is no specific singular panel of immunohistochemistry markers which can be used in all cases of metastatic liver tumors. The best use and selection of IHC markers depend upon morphological features, clinical history and results of other relevant investigations.
